Search

Non-alcoholic fatty liver disease (NAFLD) has been recently termed metabolic dysfunction-associated fatty liver disease (MAFLD) to address the strong association with the metabolic syndrome. The prevalence of MAFLD is significantly increased in obese individuals and treatment of obesity is currently the cornerstone of management of MAFLD. Bariatric and metabolic surgery nowadays emerges as a key therapeutic strategy for the treatment of the MAFLD. This review aims to provide an update on the novel studies reporting the outcomes of bariatric surgery on the spectrum of MAFLD, from hepatic steatosis to cirrhosis. [ABSTRACT FROM AUTHOR]

New endoluminal and surgical methods for the treatment of morbid obesity Abstract. A number of endoluminal techniques to treat (morbid) obesity have been developed recently aiming at finding less invasive methods that may be more acceptable for patients. Through upper endoscopy changes are made to the gastro-intestinal tract. Welldesigned trials have to prove their effectiveness and safety. In the meantime they remain experimental and this has to be communicated to the patient. New operative techniques have also been developed. The One Anastomosis Gastric Bypass is a variation of the standard Roux-Y-Gastric Bypass. There is evidence supporting that it can also become an accepted standard bariatric procedure in Switzerland.